12.07.2015 Views

The Clinical Guide to Supportive and Palliative Care for HIV/AIDS

The Clinical Guide to Supportive and Palliative Care for HIV/AIDS

The Clinical Guide to Supportive and Palliative Care for HIV/AIDS

SHOW MORE
SHOW LESS
  • No tags were found...

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

A <strong>Clinical</strong> <strong>Guide</strong> <strong>to</strong> <strong>Supportive</strong> <strong>and</strong> <strong>Palliative</strong> <strong>Care</strong> <strong>for</strong> <strong>HIV</strong>/<strong>AIDS</strong> • Chapter 3: Assessment of Physical Symp<strong>to</strong>msA full discussion of the assessment of the patient with a past his<strong>to</strong>ry of, or active involvement in,substance abuse is beyond the scope of this chapter. (For a more in-depth discussion, see Chapter11: Substance Use Problems.) <strong>The</strong> complex issues involved in the medical care of this population26 have picas been extensively reviewed in other texts. 47-50 Such care must include attention <strong>to</strong>both the <strong>HIV</strong>-related illness(es) <strong>and</strong> the substance abuse, along with the social <strong>and</strong> medicalissues that each involves. In addition, it is important that clinicians who care <strong>for</strong> people withsubstance use problems be committed <strong>to</strong> providing optimal medical care. Such care must involvesymp<strong>to</strong>m management. An ongoing relationship between the clinician <strong>and</strong> patient thatcan foster both trust <strong>and</strong> continuity of care is optimal in all cases of advanced illness <strong>and</strong> is alsodesirable in this setting.A detailed his<strong>to</strong>ry, as described in this chapter, should be undertaken in those with, or suspected<strong>to</strong> have, a his<strong>to</strong>ry of substance use problems. As in all cases of patients reporting distress,it is crucial <strong>for</strong> clinicians <strong>to</strong> focus on the detail of symp<strong>to</strong>ms <strong>and</strong> on the distress associatedwith them, in order <strong>to</strong> define the underlying pathology <strong>and</strong> diagnosis <strong>and</strong> develop a treatmentplan. <strong>Care</strong>ful assessment, combined with knowledge on the part of the clinician of pain syndromes,other symp<strong>to</strong>ms, <strong>and</strong> common symp<strong>to</strong>m complexes should facilitate the developmen<strong>to</strong>f a diagnosis <strong>and</strong> treatment plan. <strong>Care</strong>ful attention should be given specifically <strong>to</strong> assessment<strong>for</strong> concurrent psychiatric conditions, many of which have an increased prevalence in peoplewho have problems with substance use. Initially, it is important <strong>for</strong> the clinician <strong>to</strong> learn aboutthe patient’s current status with regard <strong>to</strong> drug use <strong>and</strong> the situations <strong>and</strong> triggers that, in thepast, may have prompted the patient <strong>to</strong> turn <strong>to</strong> substance abuse. Clearly not all patients will be<strong>for</strong>thcoming with in<strong>for</strong>mation relating <strong>to</strong> their substance use activities. Any inconsistenciesthat are uncovered during his<strong>to</strong>rytaking or from other clinicians or family must also be noted<strong>and</strong> their implications considered.In cases where substance abuse is being considered, eliciting the patient’s social his<strong>to</strong>ry is vital,as is speaking with others involved in the patient’s medical care, where this is possible <strong>and</strong> withrespect <strong>for</strong> privacy issues. In this context it is important <strong>to</strong> consider the concept of aberrantdrug-related behaviors. 48, 49 <strong>The</strong>se include a broad range of behaviors that have been consideredproblematic by clinicians prescribing opioids <strong>for</strong> pain. Table 3-4 presents the spectrum ofaberrant drug-related behaviors clinicians may encounter during treatment of the medically ill48, 49with prescription drugs.Table 3-4: Aberrant Drug-Related Behaviors*Behaviors more suggestiveof addictionSelling prescription drugsPrescription <strong>for</strong>geryStealing drugs from othersInjecting oral <strong>for</strong>mulationsObtaining prescription drugs fromnonmedical sourcesConcurrent abuse of alcohol or illicit drugs58U.S. Department of Health <strong>and</strong> Human Services • Health Resources <strong>and</strong> Services Administration • <strong>HIV</strong>/<strong>AIDS</strong> Bureau

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!